Why Release Parameters in Stages?
When a pharmacometric model does not converge, the difficulty may come from interactions among parameters rather than from any one parameter considered alone. For example, random-effects variability and residual error may compensate for one another, or a covariance parameter may become difficult to estimate when a variance is near its boundary. Releasing every parameter at once can make it hard to tell which part of the estimation problem is responsible.
Staged parameter release is a diagnostic workflow: temporarily hold some parameter groups fixed, fit the others, and then release additional groups in a deliberate order. The changing behavior of the optimizer can help localize a difficult interaction. This extends the earlier material on simplifying a model to localize failure: here the model and objective are held constant, while the set of parameters allowed to vary changes.
For concreteness, \(Q\) may be the negative log-likelihood for a nonlinear mixed-effects model. Parameter groups might include population structural parameters, random-effects variances and covariances, and residual-error parameters. The method does not require these particular groups, but the groups should have a clear scientific or computational interpretation.
Conditions for a Useful Staged Fit
The comparisons are informative only if the stages solve the same underlying problem. Use the same observations, model equations, likelihood definition, data processing, and numerical settings as far as practicable. Keep the objective function unchanged; if an approximation or solver setting must change, record that change and do not interpret the resulting objective difference as being due solely to parameter release.
A frozen parameter must be assigned an admissible value. Prefer a defensible starting estimate, a value from a stable fit, or a scientifically justified reference value. A poor fixed value can force the free parameters to compensate, producing a conditional fit that is numerically stable but misleading. Record which parameters are fixed, their values, which parameters are free, and the bounds or constraints applied at each stage.
The objective should be finite and sufficiently smooth near the fitted values for the optimizer’s local calculations to be meaningful. In pharmacometric models, numerical integration error, discontinuities, or unstable likelihood contributions can violate this practical condition. A reported optimizer success flag is not enough: inspect the objective, parameter estimates, gradients for free parameters, constraints, and model-specific numerical checks.
Why the Sequence Can Localize an Interaction
Suppose the full parameter vector consists of two groups, \(\psi\) and \(\phi\). In the first stage, fix \(\phi=\phi_0\) and minimize \(Q(\psi,\phi_0)\). If this conditional problem is well behaved, it provides a starting point for the next stage, where \(\phi\) is released.
The distinction between a conditional fit and a joint fit follows directly from the derivatives. At an interior joint minimum \((\psi^*,\phi^*)\), the gradient with respect to both groups must vanish. In contrast, a conditional minimum with \(\phi=\phi_0\) requires only that the derivative with respect to the free group vanish:
Thus, releasing \(\phi\) may reveal a substantial gradient, a flat or unstable direction, or a boundary problem that could not be seen while \(\phi\) was fixed. If the objective is differentiable and a stage reaches an interior minimum for its free parameters, those free-parameter gradients should be near zero, subject to numerical accuracy. At a constraint boundary, the relevant condition is instead that no feasible small move improves the objective; an unconstrained gradient need not be zero.
If the parameter space for the expanded stage includes the previous stage’s solution—for example, the newly released parameters can retain their fixed values—then the global minimum of the expanded problem cannot have a larger \(Q\) than the global minimum of the restricted problem. This is a statement about global minima, not a guarantee about optimizer output. A local optimizer may find a worse point, fail, or stop before reaching either minimum. Therefore, a change in the reported objective must be interpreted alongside convergence and numerical diagnostics.
A Practical Release Strategy
Choose a sequence that makes the outcome interpretable. A common starting strategy is to estimate the main structural parameters with selected variability and residual parameters fixed at defensible values; next release random-effects variances; then release covariance or correlation parameters; and finally estimate the residual-error parameters jointly if they have not already been released. This is not a universal order. If prior diagnostics point to a particular block, release it earlier, while retaining enough fixed structure to make the comparison useful.
Write down the free and fixed parameters for each stage. Confirm that fixed values are admissible and that all stages use the same data and objective.
Check finite objective contributions, estimates, free-parameter gradients, bounds, and model-specific numerical calculations. Save the estimates as a starting point, not as proof that all parameters are suitable.
Initialize newly free parameters at their fixed values when valid. Observe whether the objective and optimizer behavior change as that block is allowed to interact with the existing estimates.
Check the newly free parameters, their gradients or boundary conditions, covariance validity, and numerical stability. If credibility is poor, pause and diagnose rather than treating the output as a trustworthy starting point.
Once the stages are informative, estimate the intended parameter set jointly and verify that the final fit is credible. Record the sequence and results so the debugging conclusion is reproducible.
Worked Example: A Covariance Block Triggers Difficulty
Consider a hypothetical concentration-time data set fitted with a structural model for clearance and volume. Let \(Q\) be the same negative log-likelihood at every stage. The population structural parameters are denoted by \(\psi\), and random-effects parameters by \(\phi\). The analyst uses the same records, likelihood, and solver settings throughout.
Stage 1: Estimate \(\psi\) while fixing the two random-effects variances at \(0.04\) and their correlation at \(0\). The optimizer reports \(Q=412.6\), finite individual contributions, and a scaled gradient norm of \(0.003\) for the free structural parameters. These checks support using the result as a conditional starting point, although they do not establish that the fixed variability values are appropriate.
Stage 2: Release the two variances while keeping the correlation fixed at \(0\). The optimizer reports \(Q=398.2\), variances \(0.09\) and \(0.04\), and a scaled gradient norm of \(0.006\) for its free parameters. The objective has decreased by \(412.6-398.2=14.4\). The reduction is consistent with the expanded model having more freedom, but it is not by itself a hypothesis test or evidence that the variance estimates are precise.
Stage 3: Release the correlation. The optimizer moves the correlation close to \(1\), the covariance matrix becomes nearly singular, and the run stops with a large gradient for the correlation parameter. The difficulty first appears when the covariance interaction is introduced. This localizes the numerical problem to the expanded covariance block, but does not prove that the correlation alone is the cause: its interaction with the variance estimates may be responsible.
The appropriate conclusion is that Stage 2 is a checked conditional fit and Stage 3 is not a credible joint fit. Do not report Stage 3 as converged merely because it has a finite objective. Investigate whether the covariance parameterization, data support, or model assumptions can justify the near-boundary estimate, then refit and reassess the intended joint model.
Numerical Credibility Is a Separate Question
A stage is numerically credible when its output is supported by more than an optimizer’s termination message. At minimum, the objective should be finite; free estimates should be admissible; free-parameter gradients should be suitably small or satisfy the appropriate boundary conditions; and any estimated covariance matrix should meet the required positive-definiteness constraints. Also inspect predictions and residual patterns for gross implausibility, and check that numerical integration or likelihood calculations are adequate for the fitted region.
For a two-dimensional random-effects covariance matrix, positive definiteness requires positive diagonal entries and a positive determinant. A matrix can technically pass this test while being so close to singularity that estimates and derivatives are unstable. For example, the following hypothetical matrix has positive diagonal entries and a small positive determinant:
Its implied correlation is \(0.119/(\sqrt{0.16}\sqrt{0.09})=0.9917\), close to the boundary. The eigenvalues are approximately \(0.2490\) and \(0.000960\), so the smaller eigenvalue is positive but much smaller than the larger one. This is a warning to examine conditioning and sensitivity; positive definiteness alone does not establish that the covariance estimate is reliable.
Worked Example: Checking a Nearly Singular Covariance Estimate
Suppose a hypothetical intermediate fit gives the covariance matrix shown above. The variances are \(0.16\) and \(0.09\), in the squared units of the two random effects, and the covariance is \(0.119\), in the product of their units.
First calculate the determinant:
The diagonal entries are positive and the determinant is positive, so this matrix is positive definite in exact arithmetic. The standard deviations are \(0.4\) and \(0.3\), giving correlation \(0.119/(0.4\times0.3)=0.9917\). For a symmetric \(2\times2\) matrix, the eigenvalues are \((\operatorname{tr}(\Omega)\pm\sqrt{(0.16-0.09)^2+4(0.119)^2})/2\), approximately \(0.2490\) and \(0.000960\). The condition ratio of the larger to smaller eigenvalue is about \(260\).
This calculation supports a specific diagnostic conclusion: the matrix is positive definite but close to singular. It does not establish that the estimated random-effects relationship is scientifically real or precisely determined. If this matrix emerged just after a covariance block was released, inspect gradients, boundary behavior, and stability of the likelihood calculations before treating the stage as a reliable joint fit.
Worked Example: Separating a Small Gradient From Numerical Noise
In a hypothetical stage, a free parameter \(b\) is estimated near \(2.00\). To inspect the local objective, the analyst evaluates \(Q\) at \(b-h\) and \(b+h\), using \(h=0.01\). The values are \(Q(1.99)=100.013\) and \(Q(2.01)=99.987\). The central finite-difference derivative is:
The negative derivative indicates that, locally, increasing \(b\) would reduce \(Q\); a value near \(2.00\) is not supported as an interior optimum by these evaluations. But suppose tightening the numerical integration tolerance changes each objective evaluation by roughly \(0.02\). That numerical variation is large relative to the observed difference of \(0.026\) between the two evaluations, so the derivative estimate may itself be unreliable. The next step is to improve or verify the objective calculation and reassess the gradient, not to interpret the optimizer’s stopping message as decisive.
What the Stage Pattern Can—and Cannot—Tell You
A stage pattern is evidence for where to investigate, not a unique diagnosis. If one block fits credibly while fixed and the fit becomes unstable when another block is released, that block or its interaction with existing parameters deserves attention. Yet the failure may also reflect weak data support, a boundary solution, poor starting values, or numerical noise. Check these possibilities against the estimates and calculations before changing the model.
| Approach | What it contributes | Important limitation |
|---|---|---|
| Release all parameters together | Directly attempts the intended joint fit. | If it fails, it may provide little information about which block is involved. |
| Staged parameter release | Shows how fit behavior changes as parameter groups are freed. | Intermediate fits are conditional; the sequence can depend on fixed values and release order. |
| Simplify the model | Tests whether a reduced model is easier to estimate and helps localize structural complexity. | Changing the model changes the estimation problem, so it does not isolate parameter-release effects in the same way. |
Staged release does not establish identifiability, provide a final uncertainty assessment, or make a weakly supported parameter estimable. Nor does a successful restricted stage guarantee that its estimates are suitable for the full model. Use the workflow to identify where estimation becomes difficult, then evaluate the full intended model on its own merits.
Common Pitfall
A related mistake is to interpret a lower objective after release as proof that the new parameters are meaningful. Added freedom can lower the objective even when estimates are unstable or poorly supported. Numerical credibility and scientific interpretation require separate checks.
Check Your Understanding
Use the staged-estimation principles to answer the questions. Solutions follow each question.
A fit minimizes \(Q(\psi,\phi_0)\) successfully with \(\phi\) fixed. Does this show that the joint gradient is zero?
Solution: No. It supports \(\nabla_{\psi}Q(\psi^*,\phi_0)=0\) for an interior conditional minimum, but says nothing by itself about \(\nabla_{\phi}Q(\psi^*,\phi_0)\).
A stage has objective \(Q=250.0\). After releasing a parameter block, a valid global minimum of the expanded problem would be expected to be above or below this value?
Solution: It can be no higher, provided the expanded parameter space includes the original restricted solution and the objective is unchanged. The original point remains available, so the expanded global minimum is at most \(250.0\). An optimizer’s reported result can still be higher if it fails to find that minimum.
A two-parameter covariance matrix has positive variances and a positive determinant, but an estimated correlation of \(0.999\). Is positive definiteness enough to call the fit credible?
Solution: No. The matrix may be positive definite yet nearly singular. Check eigenvalues or conditioning, gradients, boundary behavior, and sensitivity before relying on the covariance estimate.
After releasing residual-error parameters, objective evaluations change by more from solver tolerance than from small parameter perturbations. What should be checked before interpreting the gradient?
Solution: Verify the numerical objective calculation, including solver accuracy and any integration or likelihood approximation. If numerical variation dominates the perturbation difference, the gradient estimate is not dependable; improve or validate the calculation and reassess.